Clinical Trials

100 enrolled

Carcinoma, Adenoid Cystic

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

140 enrolled

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT03515798 2025-09-12

PELICAN

52 enrolled

Inflammatory Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

520 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT06964906 2025-05-11

NeoHunter

140 enrolled

Breast Neoplasms

NCT05024734 2025-03-11

GAIN INST

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT05165225 2024-11-29

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

48 enrolled

Breast Neoplasms

NCT06705127 2024-11-26

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

30 enrolled

HR-positive,HER2-negative Breast Cancer

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06470633 2024-06-24

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

29 enrolled

Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

70 enrolled

Triple Negative Breast Neoplasms

NCT06404463 2024-05-08

QUEEN-Neo

76 enrolled

Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06309732 2024-03-13

GAMEC-II

36 enrolled

Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT06227065 2024-01-26

POLO

28 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05978648 2023-11-30

SMA-BC-002

116 enrolled

Breast Neoplasms

NCT02287129 2023-11-28

MEMORI

75 enrolled

Gastrointestinal

Adenocarcinoma of the Esophagogastric Junction

NCT04172259 2023-10-16

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

156 enrolled

Breast Neoplasms

NCT05983094 2023-08-09

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

181 enrolled

Breast Neoplasms

NCT05887726 2023-07-27

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

30 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

35 enrolled

Triple Negative Breast Neoplasms

NCT05816694 2023-04-18

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

50 enrolled

Thoracic

Thymoma

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

102 enrolled 10 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

62 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT05681728 2023-01-12

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

26 enrolled

Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05483439 2022-08-05

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

100 enrolled

Breast Neoplasms

NCT00496795 2022-06-29

DDP

100 enrolled

Breast Neoplasms

NCT05400993 2022-06-06

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

59 enrolled

Breast Neoplasms

NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Phase 2 Suspended

170 enrolled

Breast Neoplasms

NCT02050919 2022-03-21

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

20 enrolled 14 charts

Sarcoma

NCT02400567 2022-03-15

NeoPAL

125 enrolled

Neoadjuvant Operable Breast Cancer

NCT00193206 2021-11-23

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

123 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00193050 2021-10-26

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

110 enrolled 8 charts

Breast Neoplasms

NCT00381706 2021-09-29

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

245 enrolled 15 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03894007 2021-09-23

PREDIXIIHER2

Phase 2 Terminated

6 enrolled

Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

54 enrolled 10 charts

Breast Neoplasms

NCT03289819 2021-04-08

NIB

53 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02128243 2021-03-26

MATEO

242 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT02685059 2021-02-15

GeparNuevo

174 enrolled

Breast Neoplasms

NCT03025477 2021-02-11

CHIMOVIP